Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
The Prostate
|
October 9, 2023
TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment
Tung Hoang, Philip Sutera, Triet Nguyen, et al.
BMC Cancer
|
June 15, 2019
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)
Roche Kapoor, Matthew P Deek, Riley McIntyre, et al.
European Urology
|
May 12, 2023
Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer
Philip Sutera, Yang Song, Kim Van der Eecken, et al.
JAMA Oncology
|
March 28, 2020
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial
Ryan Phillips, William Yue Shi, Matthew Deek, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 7, 2024
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer
Jarey H Wang, Matthew P Deek, Adrianna A Mendes, et al.
European Urology Oncology
|
June 11, 2024
Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer
Philip Sutera, Yang Song, Amol C Shetty, et al.
BMC Cancer
|
June 4, 2020
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
Hamza Hasan, Matthew P Deek, Ryan Phillips, et al.
European Urology Oncology
|
September 21, 2025
Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy
Philip Sutera, Kim Van der Eecken, Yang Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2022
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial
Phuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2025
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial
Jarey H Wang, Alexander D Sherry, Soha Bazyar, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
The Prostate
|
October 9, 2023
TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment
Tung Hoang, Philip Sutera, Triet Nguyen, et al.
BMC Cancer
|
June 15, 2019
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)
Roche Kapoor, Matthew P Deek, Riley McIntyre, et al.
European Urology
|
May 12, 2023
Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer
Philip Sutera, Yang Song, Kim Van der Eecken, et al.
JAMA Oncology
|
March 28, 2020
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial
Ryan Phillips, William Yue Shi, Matthew Deek, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 7, 2024
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer
Jarey H Wang, Matthew P Deek, Adrianna A Mendes, et al.
European Urology Oncology
|
June 11, 2024
Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer
Philip Sutera, Yang Song, Amol C Shetty, et al.
BMC Cancer
|
June 4, 2020
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
Hamza Hasan, Matthew P Deek, Ryan Phillips, et al.
European Urology Oncology
|
September 21, 2025
Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy
Philip Sutera, Kim Van der Eecken, Yang Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2022
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial
Phuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2025
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial
Jarey H Wang, Alexander D Sherry, Soha Bazyar, et al.
Page
of 9